What is Alto Neuroscience's net investment in lease?

Alto Neuroscience (ANRO) reported net investment in lease of $4.06M in Q1 2026.

How has Alto Neuroscience's net investment in lease changed year-over-year?

Alto Neuroscience's net investment in lease decreased by 16.2% year-over-year, from $4.85M to $4.06M.

Alto Neuroscience ANRO Net Investment in Lease

Net Investment in Lease at other companies

Xenon PharmaceuticalsXENE

——

Acadia PharmaceuticalsACAD

——

Rapport Therapeutics, Inc.RAPP

——

Praxis Precision Medicines, Inc.PRAX

——

MeiraGTx Holdings plcMGTX

——

LBR

LB Pharmaceuticals Inc Common StockLBRX

——

Other financials

Income statement

See full

Operating income-$27.1M-73.1%

Net income-$26.2M-73.0%

EPS (diluted)-$0.80-42.9%

Balance sheet

See full

Cash & equivalents$264.3M+63.9%

Total debt$20.9M-17.2%

Total equity$243.4M+75.0%

Total assets$276.3M+60.7%

Cash flow

See full

Operating cash flow-$27.1M-63.6%

CapEx$556.0K+2,217%

Free cash flow-$27.6M-66.7%

Valuation

See full

Market cap$874.19M+1,358%

Enterprise value$630.81M-958%

Returns & leverage

See full

Return on equity-38.9%+0.9pp

Debt / equity0.1×-0.1×

Current ratio20.5×-2.0×

Where this comes from

Reported directly by Alto Neuroscience in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alto Neuroscience's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alto Neuroscience's net investment in lease?: Alto Neuroscience (ANRO) reported net investment in lease of $4.06M in Q1 2026.
How has Alto Neuroscience's net investment in lease changed year-over-year?: Alto Neuroscience's net investment in lease decreased by 16.2% year-over-year, from $4.85M to $4.06M.